Treatment to cure: Advancing AAV gene therapy manufacture

•Gene therapy market analysis demonstrates prevalence of AAV.•AAV production methodologies must address the need to produce multiple serotypes for tissue tropism.•Scalable manufacturing solutions are required to realise product potential.•Challenges for manufacture remain with particular focus on producing high quality ‘full’ viral vector.•Disruptive technology and future innovation provide further opportunities for manufacture of these complex molecules.